NEW YORK, April 22, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Boston Scientific
Corporation (NYSE:BSX), Thermo Fisher Scientific Inc. (NYSE:TMO),
Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Jazz
Pharmaceuticals plc (NASDAQ:JAZZ). Private wealth members receive
these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.analystsreview.com/1204-100free
--
Alexion Pharmaceuticals, Inc. Analyst Notes
On April 11, 2014, Alexion
Pharmaceuticals, Inc. (Alexion) announced that it will present new
data from the extension phase of two clinical studies, examining
the long-term efficacy and safety of asfotase alfa in infants and
juveniles with hypophosphatasia (HPP) - an inherited, ultra-rare
metabolic disorder. Alexion stated that it will present the said
data along with presentation of results from a retrospective
natural history study of patients with perinatal and infantile HPP
at the joint meeting of the Pediatric Academic Societies (PAS) and
the Asian Society for Pediatric Research which is scheduled on
May 3 to May 6, 2014 in Vancouver, B.C., Canada. Alexion also stated that several
abstracts summarizing the asfotase alfa studies and the HPP natural
history study will also be presented via poster session during the
meeting. The full analyst notes on Alexion Pharmaceuticals, Inc.
are available to download free of charge at:
http://www.analystsreview.com/1204-ALXN-22Apr2014.pdf
--
Boston Scientific Corporation Analyst Notes
On April 10, 2014, Boston
Scientific Corporation (Boston Scientific) reported that it has
enrolled its first patient in a new registry to evaluate clinical
outcomes and the economic value of the Vercise™ Deep Brain
Stimulation (DBS) System in patients with Parkinson's disease (PD).
According to the Company, the Vercise DBS System is an implantable
medical device which will enable customized therapy, helping to
improve the quality of life for PD patients. Prof. Dr. Vesper,
Department of Functional Neurosurgery and Stereotaxy at
Heinrich-Heine University Hospital in Dusseldorf, Germany, remarked, "The unique
features of the Vercise System, including the ability to
selectively stimulate targeted areas of the brain via multiple
independent current control, as well as the longevity of the Zero
Volt™ battery, are designed for improved patient outcomes and
enhanced clinical effectiveness." Boston Scientific expects to
enroll up to 300 patients in the study with PD. The full analyst
notes on Boston Scientific Corporation are available to download
free of charge at:
http://www.analystsreview.com/1204-BSX-22Apr2014.pdf
--
Thermo Fisher Scientific Inc. Analyst Notes
Thermo Fisher Scientific Inc. posted on its events page that it
will hold its Q1 2014 earning conference call on Wednesday, April 23, 2014, at 8:30 a.m. ET. The live webcast of the call will
be made available at the Company's website. The full analyst notes
on Thermo Fisher Scientific Inc. are available to download free of
charge at:
http://www.analystsreview.com/1204-TMO-22Apr2014.pdf
--
Valeant Pharmaceuticals Intl Inc Analyst Notes
On April 11, 2014, shares in
Valeant Pharmaceuticals Intl Inc. (Valeant) dropped 3.68% to end
trading at $118.79. Over the past
six-month trading period, Valeant's shares gained 8.55%, in line
with the Dow Jones Industrial Average which increased by 5.18%
during the same trading period. The full analyst notes on Valeant
Pharmaceuticals Intl Inc are available to download free of charge
at:
http://www.analystsreview.com/1204-VRX-22Apr2014.pdf
--
Jazz Pharmaceuticals plc Analyst Notes
On April 11, 2014, Jazz
Pharmaceuticals plc's (Jazz Pharmaceuticals) stock price slipped by
0.77% to close trading at $128.61 per
share. Over the five-day trading period, Jazz Pharmaceuticals'
stock fared better with a 1.43% increase, compared with the Nasdaq
Composite which dropped 3.10% during that same period. The full
analyst notes on Jazz Pharmaceuticals plc are available to download
free of charge at:
http://www.analystsreview.com/1204-JAZZ-22Apr2014.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review